- BioVaxys Technology (CSE:BIOV) reveals that its DPX technology outperforms traditional aqueous and emulsion-based delivery systems by effectively recruiting and activating antigen-presenting cells
- DPX maintains antigen at the injection site, ensuring sustained immune response and activation of critical T cell markers, even without antigen cargo
- Collaborative research with Dalhousie University demonstrated significant immune cell infiltration and responses, highlighting DPX’s potential in the cancer vaccine market
- Shares of BioVaxys Technology are down 6.67 per cent to C$0.07 as of 12:06 pm ET
BioVaxys Technology (CSE: BIOV) has revealed significant findings from studies evaluating its innovative immune-educating delivery platform, DPX.
In a news release, the company stated that the research highlights that DPX effectively recruits and activates unique subsets of antigen-presenting cells (APCs), demonstrating superior immune activation compared with traditional aqueous and emulsion-based antigen delivery systems.
The success of cancer vaccines heavily depends on the effective delivery of antigenic APCs, which prime cytotoxic T cells to eradicate tumors.
Conventional peptide antigen delivery methods face limitations: water-based formulations provide only brief exposure to immune cells, while oil-in-water emulsions can lead to dysfunctional T-cell responses.
“These groundbreaking study results validate our strategic position in the multi-billion drug delivery market,” James Passin, CEO of BioVaxys, said in a statement. “DPX not only outperforms current solutions but also opens up significant revenue potential across various market segments.”
In contrast, BioVaxys’ DPX platform employs a non-aqueous, lipid-in-oil formulation that maintains the antigen at the injection site. This design ensures that the uptake of DPX-encapsulated antigens is actively driven by APCs over an extended period.
A collaborative study with Dalhousie University assessed the immune response dynamics of DPX compared with other formulations. Researchers utilized advanced techniques such as multi-parameter flow cytometry and confocal microscopy to analyze immune cell composition and antigen uptake in mice. The immune responses were evaluated through the interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) assay, a sensitive method for measuring immune cell activity.
Key findings from the study revealed:
- Enhanced APC recruitment: Both DPX and oil emulsions were effective in attracting APCs to the injection site, significantly increasing immune cell infiltration within two days of DPX injection. However, DPX showed superior activation of crucial T cell markers compared with emulsions.
- Inherent immune activation: Notably, the DPX platform activated T cell subsets even without antigen cargo, indicating its potential as an immune-activating agent on its own.
“These findings underscore the quantitative and qualitative advantages of DPX in immune cell recruitment, showcasing its potential to enhance the efficacy of antigen delivery in immunotherapies,” Kenneth Kovan, COO of BioVaxys Technology, said.
As BioVaxys continues to advance its innovative technologies, these results position the company at the forefront of the evolving drug delivery landscape.
BioVaxys Technology is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields.
Shares of BioVaxys Technology Corp. (CSE:BIOV) are down 6.67 per cent to C$0.07 as of 12:06 pm ET.
Join the discussion: Find out what everybody’s saying about this stock on the BioVaxys Technology Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Adobe Stock)